ArticlebioRxiv : the preprint server for biology2026
VICAST: An Integrated Toolkit for Viral Genome Annotation Curation and Low-Frequency Variant Analysis in Passage Studies.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cultured virus passage studies are fundamental to understanding viral evolution, attenuation, and host adaptation, yet analyzing genomic changes across passages requires both accurate functional annotation of viral genomes and sensitive detection of low-frequency variants. Existing tools address these needs separately: automated annotation pipelines such as VADR and VIGOR4 perform well for well-characterized virus families but struggle with poorly-annotated or novel genomes, while variant calling pipelines designed for clinical diagnostics focus on consensus sequences rather than the low-frequency variants (3-50% frequency) that are biologically meaningful in passage studies. Here we present VICAST (Viral Cultured-virus Annotation and SnpEff Toolkit), an integrated software suite that combines semi-automated genome annotation with manual curation checkpoints and low-frequency variant calling optimized for viral populations. VICAST provides four annotation pathways to accommodate diverse genome annotation quality, including polyproteins, unannotated and multi-segmented genomes. It integrates with SnpEff for functional variant annotation and includes a BAM-level read co-occurrence module for haplotype validation. We validated VICAST using publicly available datasets from three virus families representing distinct analytical challenges: SARS-CoV-2 for polyprotein cleavage-aware annotation, Dengue virus 2 for standard flavivirus annotation and low-frequency variant detection, and Influenza A H1N1 for multi-segmented genome handling. Additionally, VICAST's annotation curation workflow has produced validated annotations not available from NCBI, including protein-level annotations for Chikungunya virus (NC_004162.2). These curated annotations have been incorporated into a custom SnpEff database distributed with VICAST, enabling immediate functional variant annotation for Chikungunya without requiring users to build the database from scratch. Benchmark comparisons with VADR demonstrate VICAST's advantages for passage study workflows, including 5.6-8.1 times faster processing and integrated contamination screening. VICAST is freely available at https://github.com/mihinduk/VICAST and distributed as both Docker containers and conda-based installations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.